Immuno-Oncology in China
Home



Clinical Trial Results

基于改良 FOLFIRINOX 方案的新辅助治疗在中国人群局部晚期胰腺癌预后的相关性
Association of Modified‐FOLFIRINOX‐Regimen‐Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population
Li, Shunliang Gao, Risheng Que, Jianying Lou, Risheng Yu, Ying Yuan, Qichun Wei, Pintong Huang, Tingbo Liang, Xueli Bai
The Oncologist 2019; 24:301-e93; first published on November 20, 2018; doi:10.1634/theoncologist.2018-0696

用于癌症诱发的骨病患者的新型骨靶向阿糖胞苷 - 依替膦酸钠结合物 MBC-11 的首次人体 I 期研究
First‐in‐Human Phase I Study of MBC‐11, a Novel Bone‐Targeted Cytarabine‐Etidronate Conjugate in Patients with Cancer‐Induced Bone Disease
Shawn Patrick Zinnen, Alexander Karpeisky, Daniel D. Von Hoff, Larisa Plekhova, Alexander Alexandrov
The Oncologist 2019; 24:303-e102; first published on November 9, 2018; doi:10.1634/theoncologist.2018-0707


Breast Cancer

在激素受体阳性、人类表皮生长因子受体 2 阴性晚期乳腺癌的治疗中,探索磷酸肌醇 3-激酶通路激活的生物标志物
Exploring Biomarkers of Phosphoinositide 3‐Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer
Virginia G. Kaklamani, Andrea L. Richardson, Carlos L. Arteaga
The Oncologist 2019; 24:305-312; first published on January 16, 2019; doi:10.1634/theoncologist.2018-0314

原发 IV 期人表皮生长受体 2 (HER2) 阳性乳腺癌的HER2 靶向治疗的长期存活
Long‐Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2‐Targeted Therapy
Yao Wong, Akshara Singareeka Raghavendra, Christos Hatzis, Javier Perez Irizarry, Teresita Vega, Nina Horowitz, Carlos H. Barcenas, Mariana Chavez‐MacGregor, Vicente Valero, Debu Tripathy, Lajos Pusztai, Rashmi K. Murthy
The Oncologist 2019; 24:313-318; first published on August 23, 2018; doi:10.1634/theoncologist.2018-0213


Gastrointestinal Cancer

患者年龄对左侧结直肠肿瘤分子变异的影响
Impact of Patient Age on Molecular Alterations of Left‐Sided Colorectal Tumors
Alberto Puccini, Heinz‐Josef Lenz, John L. Marshall, David Arguello, Derek Raghavan, W. Michael Korn, Benjamin A. Weinberg, Kelsey Poorman, Arielle L. Heeke, Philip A. Philip, Anthony F. Shields, Richard M. Goldberg, Mohamed E. Salem
The Oncologist 2019; 24:319-326; first published on July 17, 2018; doi:10.1634/theoncologist.2018-0117

响应贝伐珠单抗联合奥沙利铂或伊立替康为基础的化疗治疗转移性结直肠癌患者的预测性生物标志物的 aCGH 分析
aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin‐ or Irinotecan‐Based Chemotherapy in Patients with Metastatic Colorectal Cancer
Yoshihiko Fujita, Masataka Taguri, Kentaro Yamazaki, Junji Tsurutani, Kazuko Sakai, Takahiro Tsushima, Michitaka Nagase, Hiroshi Tamagawa, Shinya Ueda, Takao Tamura, Yasushi Tsuji, Kohei Murata, Koichi Taira, Tadamichi Denda, Toshikazu Moriwaki, Sadao Funai, Takako Eguchi Nakajima, Kei Muro, Akihito Tsuji, Motoki Yoshida, Koichi Suyama, Takuya Kurimoto, Naotoshi Sugimoto, Eishi Baba, Nobuhiko Seki, Mikio Sato, Takaya Shimura, Narikazu Boku, Ichinosuke Hyodo, Takeharu Yamanaka, Kazuto Nishio
The Oncologist 2019; 24:327-337; first published on November 13, 2018; doi:10.1634/theoncologist.2018-0119

在氟尿嘧啶 - 奥沙利铂辅助化疗期间二甲双胍的使用和糖尿病状态对已切除结肠癌患者预后的影响:TOSCA 研究亚分析
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine‐Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis
Claudio Vernieri, Fabio Galli, Laura Ferrari, Paolo Marchetti, Sara Lonardi, Evaristo Maiello, Rosario V. Iaffaioli, Maria G. Zampino, Alberto Zaniboni, Sabino De Placido, Maria Banzi, Azzurra Damiani, Daris Ferrari, Gerardo Rosati, Roberto F. Labianca, Paolo Bidoli, Giovanni L. Frassineti, Mario Nicolini, Lorenzo Pavesi, Maria C. Tronconi, Angela Buonadonna, Sabrina Ferrario, Giovanni Lo Re, Vincenzo Adamo, Emiliano Tamburini, Mario Clerico, Paolo Giordani, Francesco Leonardi, Sandro Barni, Andrea Ciarlo, Luigi Cavanna, Stefania Gori, Saverio Cinieri, Marina Faedi, Massimo Aglietta, Maria Antista, Katia F. Dotti, Francesca Galli, Maria Di Bartolomeo, on behalf of TOSCA (Three or Six Colon Adjuvant) Investigators
The Oncologist 2019; 24:385-393; first published on January 3, 2019; doi:10.1634/theoncologist.2018-0442